Market Overview

UPDATE: Morgan Stanley Reiterates On Celgene Ahead Of Markman Hearing

Related CELG
American Air, Bank Of America, Celgene, Netflix: Fast Money Picks For July 12
Merck Falls As FDA Puts Hold On 3 Keytruda Myeloma Studies
Anderson Hoagland & Co Buys Enterprise Financial Services Corp, Novanta Inc, Siemens AG, ... (GuruFocus)

In a report published Monday, Morgan Stanley analyst Matthew Harrison reiterated an Equal-Weight rating on Celgene (NASDAQ: CELG), but removed the $150.00 price target.

In the report, Morgan Stanley noted, “The Markman hearing's main purpose is for Celgene and Natco (the generic filer) to present their arguments on disputed claims in Revlimid's patents (e.g., the def. of hemihydrate). There are 9 broad areas of claims in dispute (see inside for detailed analysis of each claim). Importantly, there will be no ruling or decision at the Markman hearing.

"We would expect the Judge (Susan Wigenton) not to rule until the fall (while there is no set timeline for a ruling, rulings generally take ~3 months). We would expect the patent trial to begin in 2015.”

Celgene closed on Friday at $146.67.

Latest Ratings for CELG

Jul 2017JefferiesAssumesBuy
Jun 2017BTIG ResearchDowngradesBuyNeutral
Jun 2017Leerink SwannUpgradesMarket PerformOutperform

View More Analyst Ratings for CELG
View the Latest Analyst Ratings

Posted-In: Matthew Harrison Morgan StanleyAnalyst Color Price Target Analyst Ratings


Related Articles (CELG)

View Comments and Join the Discussion!